J. Kleim

发表

Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase.

R. Kirsch, J. Kleim, R. Bender, 1994, Virology.

The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.

A. D. Clark, Jianping Ding, P. Boyer, 2001, Journal of molecular biology.

Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-did

E. De Clercq, J. Balzarini, M. Roesner, 1998, Biochemical pharmacology.

Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine.

E. De Clercq, J. Balzarini, M. Roesner, 1997, The Journal of infectious diseases.

A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group.

M. Ait-Khaled, M. Tisdale, J. Kleim, 1999, Journal of acquired immune deficiency syndromes.

Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases.

D. Stammers, C. Nichols, Jingshan Ren, 2007, Journal of medicinal chemistry.

Graded cytopathogenicity of the human immunodeficiency virus (HIV) in the course of HIV infection

H. Brackmann, K. Schneweis, J. Kleim, 2004, Medical Microbiology and Immunology.

Absence of human immunodeficiency virus (HIV) proviral sequences in seronegative hemophilic men and sexual partners of HIV‐seropositive hemophiliacs

H. Brackmann, K. Schneweis, J. Kleim, 1992, Transfusion.

Latent human herpesvirus-6 DNA is sparsely distributed in peripheral blood lymphocytes of healthy adults and patients with lymphocytic disorders

K. Schneweis, J. Kleim, T. Sandhoff, 2004, Medical Microbiology and Immunology.

HBY 097 - a second-generation nonnucleoside inhibitor of the HIV-1 reverse transcriptase

J. Kleim, 1998 .

Comparison of different methods for detecting human immune deficiency virus in human immunodeficiency virus‐seropositive hemophiliacs

K. Schneweis, J. Kleim, R. Ruff, 1989, Journal of medical virology.

Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria

W. Monteiro, M. Lacerda, B. Angus, 2019, The New England journal of medicine.

Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers

Ann K. Miller, F. Nosten, L. Luzzatto, 2017, The American journal of tropical medicine and hygiene.

Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.

E. De Clercq, J. Balzarini, E. Clercq, 2000, AIDS research and human retroviruses.

Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group.

T. Merigan, M. Winters, J. Balzarini, 1999, The Journal of infectious diseases.

Rational Dose Selection for a Nonnucleoside Reverse Transcriptase Inhibitor through Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation

G. Drusano, W. Prince, J. Kleim, 2002, Antimicrobial Agents and Chemotherapy.

Acute HIV-1 Infection in Patients with Hemophilia B Treated with β-Propiolactone-UV-lnactivated Clotting Factor

J. Oldenburg, H. Brackmann, K. Schneweis, 1990, Thrombosis and Haemostasis.

Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication

R. Kaiser, M. Wichers, R. Kirsch, 1995, Antimicrobial agents and chemotherapy.

Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720

E. De Clercq, J. Balzarini, A. Karlsson, 1994, Journal of virology.

Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.

E. Arnold, R. Kirsch, Y. Hsiou, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication

Christoph, J. Kleim, R. Bender, 1993, Antimicrobial Agents and Chemotherapy.

GW420867X Administered to HIV-1-Infected Patients Alone and in Combination with Lamivudine and Zidovudine

R. Wood, W. Prince, A. Jones, 2001, HIV clinical trials.

Diagnosis of acute and latent varicella‐zoster virus infections using the polymerase chain reaction

E. Bierhoff, A. Eis-Hübinger, K. Schneweis, 1991, Journal of medical virology.

Inducible expression of herpes simplex virus type 1 glycoprotein C in NIH 3T3 cells.

A. Eis-Hübinger, K. Schneweis, J. Kleim, 1990, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

Changes in Human Immunodeficiency Virus Type 1 Gag at Positions L449 and P453 Are Linked to I50V Protease Mutants In Vivo and Cause Reduction of Sensitivity to Amprenavir and Improved Viral Fitness In Vitro

R. Elston, T. Wrin, C. Petropoulos, 2002, Journal of Virology.

Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1

R. Esnouf, E. De Clercq, A. Vandamme, 1997, Journal of virology.

Sensitivity of (138 Glu-->Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors.

E. De Clercq, J. Balzarini, A. Karlsson, 1994, Biochemical and biophysical research communications.

Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, J. Balzarini, A. Karlsson, 1996, Proceedings of the National Academy of Sciences of the United States of America.

In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097.

R. Kirsch, J. Kleim, A. Paessens, 1997, Virology.

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study

S. Krudsood, M. Lacerda, A. Llanos-Cuentas, 2014, The Lancet.

Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.

S. Stinnett, A. Beelen, S. Duparc, 2013, British journal of clinical pharmacology.

Diversification of HIV-1 strains after infection from a unique source.

R. Kaiser, J. Oldenburg, P. Kasper, 1993, AIDS research and human retroviruses.

Epidemiologically closely related viruses from hemophilia B patients display high homology in two hypervariable regions of the HIV-1 env gene.

M. Gahr, H. Brackmann, K. Schneweis, 1991, AIDS research and human retroviruses.

Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype

R. Esnouf, E. De Clercq, C. Pannecouque, 2001, AIDS.

Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies

R. Harrigan, M Tisdale, M. Tisdale, 2000, AIDS.

Inclusion of full length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibility phenotyping.

C. Gale, J. Kleim, L. Robinson, 2002, Journal of virological methods.

Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.

A. D. Clark, Jianping Ding, S. Hughes, 1998, Journal of molecular biology.

Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study

I. Elyazar, R. Noviyanti, D. Subekti, 2023, The Lancet. Infectious diseases.

Detection of latent thymidine kinase-deficient herpes simplex virus in trigeminal ganglia of mice using the polymerase chain reaction

K. Schneweis, J. Kleim, A. Friedrich, 2005, Archives of Virology.

Antiviral Activity and Safety of Aplaviroc with Lamivudine/Zidovudine in HIV-Infected, Therapy-Naive Patients: The ASCENT (CCR102881) Study

A. Lazzarin, J. Currier, N. Clumeck, 2008, Antiviral Therapy.

R. Elston, T. Wrin, C. Petropoulos, 2002, Journal of Virology.